A 58-year-old Indian man presents to the ophthalmology clinic for routine eye examination. He is asymptomatic and has no ocular complaints. On examination, visual acuity is 6/6 in both eyes. Intraocular pressure (IOP) measured by applanation tonometry is 24 mmHg in the right eye and 22 mmHg in the left eye. Gonioscopy reveals an open angle (Shaffer grade III–IV) bilaterally. Optic disc examination shows a vertical cup-to-disc ratio of 0.7 in the right eye and 0.65 in the left eye, with inferior neuroretinal rim thinning and a flame-shaped hemorrhage at the disc margin of the right eye. Automated perimetry shows a superior arcuate defect in the right eye. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient has **Primary Open-Angle Glaucoma (POAG)** with evidence of both structural (optic disc cupping, neuroretinal rim loss, disc hemorrhage) and functional (superior arcuate visual field defect) damage. **Key Point:** The presence of elevated IOP (24 mmHg), open angles on gonioscopy, optic nerve head damage (cup-to-disc ratio 0.7, inferior rim thinning, disc hemorrhage), and corresponding visual field loss (arcuate defect) confirms POAG with documented glaucomatous damage. ## Management Algorithm ```mermaid flowchart TD A[POAG diagnosed with glaucomatous damage]:::outcome --> B{IOP target achieved?}:::decision B -->|No| C[Initiate medical therapy]:::action C --> D[Prostaglandin analog as first-line]:::action D --> E[Reassess in 4 weeks]:::action E --> F{Target IOP reached?}:::decision F -->|Yes| G[Continue monotherapy + monitoring]:::action F -->|No| H[Add second agent or escalate]:::action B -->|Yes| I[Continue current regimen]:::action H --> J{Adequate control?}:::decision J -->|No| K[Consider laser or surgery]:::action ``` ## Treatment Rationale **High-Yield:** In POAG with documented glaucomatous damage (optic nerve changes + visual field loss), IOP reduction is the only proven modifiable risk factor. Current IOP of 24 mmHg is above target for a patient with existing damage. **Clinical Pearl:** Prostaglandin analogs (latanoprost, travoprost, bimatoprost) are the most effective first-line agents, reducing IOP by 25–35%. They have once-daily dosing, minimal systemic side effects, and superior efficacy compared to beta-blockers or alpha-2 agonists. **Key Point:** The right eye shows more advanced disease (higher cup-to-disc ratio, disc hemorrhage, visual field loss), so it requires treatment initiation. The left eye (cup-to-disc 0.65, no field loss) may be monitored initially, though treatment of both eyes is often considered given the bilateral IOP elevation. ## Why This Option Is Correct 1. **Documented glaucomatous damage** (optic nerve + visual field loss) mandates IOP-lowering therapy. 2. **Prostaglandin analogs** are guideline-recommended first-line agents for POAG. 3. **Monotherapy** is appropriate as initial therapy; escalation occurs only if target IOP is not achieved. 4. **Right eye prioritization** reflects the side with greater structural and functional damage.